Published in Expert Opin Biol Ther on January 01, 2005
Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol (2007) 2.59
A robust pipeline for rapid production of versatile nanobody repertoires. Nat Methods (2014) 1.46
Nanobody-aided structure determination of the EpsI:EpsJ pseudopilin heterodimer from Vibrio vulnificus. J Struct Biol (2008) 1.27
Nanobody: the "magic bullet" for molecular imaging? Theranostics (2014) 1.04
Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. Gene Ther (2012) 0.99
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody. Nucl Med Biol (2012) 0.95
Bispecific antibodies and their applications. J Hematol Oncol (2015) 0.92
Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med (2014) 0.91
Generation and characterization of non-competitive furin-inhibiting nanobodies. Biochem J (2012) 0.89
5th European Antibody Congress 2009: November 30–December 2, 2009, Geneva, Switzerland. MAbs (2011) 0.87
Nanodrug delivery systems: a promising technology for detection, diagnosis, and treatment of cancer. AAPS PharmSciTech (2014) 0.85
A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity. J Biol Chem (2009) 0.84
Development of VHH antibodies against dengue virus type 2 NS1 and comparison with monoclonal antibodies for use in immunological diagnosis. PLoS One (2014) 0.83
Adenoviral targeting using genetically incorporated camelid single variable domains. Lab Invest (2014) 0.83
Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles (2016) 0.82
Efficient, chemoselective synthesis of immunomicelles using single-domain antibodies with a C-terminal thioester. BMC Biotechnol (2009) 0.82
Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies. Leukemia (2013) 0.77
Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells. Biochim Biophys Acta (2015) 0.77
Resurfaced cell-penetrating nanobodies: A potentially general scaffold for intracellularly targeted protein discovery. Protein Sci (2016) 0.77
Improved cancer therapy and molecular imaging with multivalent, multispecific antibodies. Cancer Biother Radiopharm (2010) 0.77
Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy. Theranostics (2015) 0.77
Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy. Bioimpacts (2013) 0.77
A 45-Amino-Acid Scaffold Mined from the PDB for High-Affinity Ligand Engineering. Chem Biol (2015) 0.77
Contributions of conventional and heavy-chain IgG to immunity in fetal, neonatal, and adult alpacas. Clin Vaccine Immunol (2010) 0.76
Single domain antibodies for the knockdown of cytosolic and nuclear proteins. Protein Sci (2017) 0.75
Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine (2017) 0.75
Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein. Mol Ther Oncolytics (2015) 0.75
Characterization of single-domain antibodies against Foot and Mouth Disease Virus (FMDV) serotype O from a camelid and imaging of FMDV in baby hamster kidney-21 cells with single-domain antibody-quantum dots probes. BMC Vet Res (2015) 0.75
Pichia pastoris Mut(S) strains are prone to misincorporation of O-methyl-L-homoserine at methionine residues when methanol is used as the sole carbon source. Microb Cell Fact (2016) 0.75
Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood (2008) 7.15
Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature (2003) 4.33
A versatile nanotrap for biochemical and functional studies with fluorescent fusion proteins. Mol Cell Proteomics (2007) 4.28
Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res (2010) 4.25
Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol (2002) 3.89
Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods (2006) 3.12
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
Arginase-1 and Ym1 are markers for murine, but not human, alternatively activated myeloid cells. J Immunol (2005) 2.75
Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A (2006) 2.51
Single-domain antibody fragments with high conformational stability. Protein Sci (2002) 2.31
Macrophage galactose-type C-type lectins as novel markers for alternatively activated macrophages elicited by parasitic infections and allergic airway inflammation. J Leukoc Biol (2004) 2.30
Modulation of protein properties in living cells using nanobodies. Nat Struct Mol Biol (2009) 2.15
ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods (2007) 2.04
Alternatively activated macrophages during parasite infections. Trends Parasitol (2004) 2.01
Functional identification of the alveolar edema reabsorption activity of murine tumor necrosis factor-alpha. Am J Respir Crit Care Med (2003) 1.98
Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology (2006) 1.96
Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood (2009) 1.92
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J Immunol (2005) 1.86
Trypanosoma brucei modifies the tsetse salivary composition, altering the fly feeding behavior that favors parasite transmission. PLoS Pathog (2010) 1.77
Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathog (2010) 1.70
Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis (2006) 1.68
Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res (2012) 1.67
A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature (2003) 1.66
Peroxisome proliferator-activated receptor gamma (PPARgamma) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood (2006) 1.65
General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem (2008) 1.60
Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol (2008) 1.57
Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem (2003) 1.54
Three camelid VHH domains in complex with porcine pancreatic alpha-amylase. Inhibition and versatility of binding topology. J Biol Chem (2002) 1.51
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res (2013) 1.46
Efficient cancer therapy with a nanobody-based conjugate. Cancer Res (2004) 1.46
Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med (2008) 1.45
Crystal structure of the intrinsically flexible addiction antidote MazE. J Biol Chem (2003) 1.45
Identification of a common gene signature for type II cytokine-associated myeloid cells elicited in vivo in different pathologic conditions. Blood (2006) 1.43
Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions. Int J Dev Biol (2011) 1.41
Identification of a universal VHH framework to graft non-canonical antigen-binding loops of camel single-domain antibodies. J Mol Biol (2005) 1.41
MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol (2007) 1.39
Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer (2002) 1.36
Myeloid-derived suppressor cells in parasitic infections. Eur J Immunol (2010) 1.36
IL-10 dampens TNF/inducible nitric oxide synthase-producing dendritic cell-mediated pathogenicity during parasitic infection. J Immunol (2009) 1.35
Alternatively activated macrophages in protozoan infections. Curr Opin Immunol (2007) 1.30
Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem (2004) 1.28
Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy. ACS Nano (2011) 1.24
Antibody repertoire development in camelids. Dev Comp Immunol (2006) 1.23
Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells. J Immunol (2003) 1.23
The induction of a type 1 immune response following a Trypanosoma brucei infection is MyD88 dependent. J Immunol (2005) 1.23
Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations. J Mol Biol (2004) 1.21
The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur J Immunol (2005) 1.21
Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res (2012) 1.20
Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med (2006) 1.20
Secretory leukocyte protease inhibitor promotes the tumorigenic and metastatic potential of cancer cells. Proc Natl Acad Sci U S A (2003) 1.19
Adenylate cyclases of Trypanosoma brucei inhibit the innate immune response of the host. Science (2012) 1.19
Secretory leukocyte protease inhibitor in cancer development. Ann N Y Acad Sci (2004) 1.18
Disulfide bond introduction for general stabilization of immunoglobulin heavy-chain variable domains. J Mol Biol (2008) 1.17
Alternatively activated myeloid cells limit pathogenicity associated with African trypanosomiasis through the IL-10 inducible gene selenoprotein P. J Immunol (2008) 1.16
Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood (2011) 1.15
VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI'. Mol Immunol (2008) 1.15
Nanobodies and their potential applications. Nanomedicine (Lond) (2013) 1.14
Interferon-gamma and nitric oxide in combination with antibodies are key protective host immune factors during trypanosoma congolense Tc13 Infections. J Infect Dis (2006) 1.12
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol (2008) 1.12
Minimum information about a protein affinity reagent (MIAPAR). Nat Biotechnol (2010) 1.10
Engineering camel single-domain antibodies and immobilization chemistry for human prostate-specific antigen sensing. Anal Chem (2005) 1.10
The role of B-cells and IgM antibodies in parasitemia, anemia, and VSG switching in Trypanosoma brucei-infected mice. PLoS Pathog (2008) 1.09
African trypanosomiasis: naturally occurring regulatory T cells favor trypanotolerance by limiting pathology associated with sustained type 1 inflammation. J Immunol (2007) 1.09
P75 tumor necrosis factor-receptor shedding occurs as a protective host response during African trypanosomiasis. J Infect Dis (2004) 1.08
A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J (2010) 1.08
Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J (2011) 1.08
A case of convergence: why did a simple alternative to canonical antibodies arise in sharks and camels? PLoS Biol (2011) 1.07
Nanobodies as tools for in vivo imaging of specific immune cell types. J Nucl Med (2010) 1.07
Myeloid-derived suppressor cells infiltrate the heart in acute Trypanosoma cruzi infection. J Immunol (2011) 1.05
Prostate-specific antigen immunosensing based on mixed self-assembled monolayers, camel antibodies and colloidal gold enhanced sandwich assays. Biosens Bioelectron (2004) 1.04
An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug Chem (2004) 1.04
Pivotal Advance: Arginase-1-independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J Leukoc Biol (2012) 1.04
Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J Immunol (2005) 1.04
Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med (2013) 1.03
Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol (2005) 1.02
High affinity nanobodies against the Trypanosome brucei VSG are potent trypanolytic agents that block endocytosis. PLoS Pathog (2011) 1.01
Strong in vivo maturation compensates for structurally restricted H3 loops in antibody repertoires. J Biol Chem (2005) 1.01
Macrophage reprogramming by mycolic acid promotes a tolerogenic response in experimental asthma. Am J Respir Crit Care Med (2006) 1.01
Tsetse fly saliva biases the immune response to Th2 and induces anti-vector antibodies that are a useful tool for exposure assessment. Int J Parasitol (2006) 1.01
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol (2011) 1.00
Engineering a camelid antibody fragment that binds to the active site of human lysozyme and inhibits its conversion into amyloid fibrils. Biochemistry (2008) 1.00
In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med (2010) 0.99
African trypanosomosis: from immune escape and immunopathology to immune intervention. Vet Parasitol (2007) 0.98
Transcriptome analysis of monocyte-HIV interactions. Retrovirology (2010) 0.98
SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med (2013) 0.97
Expression and extracellular release of a functional anti-trypanosome Nanobody® in Sodalis glossinidius, a bacterial symbiont of the tsetse fly. Microb Cell Fact (2012) 0.97
Parallel selection of multiple anti-infectome Nanobodies without access to purified antigens. J Immunol Methods (2007) 0.97
Tumor necrosis factor (TNF) receptor-1 (TNFp55) signal transduction and macrophage-derived soluble TNF are crucial for nitric oxide-mediated Trypanosoma congolense parasite killing. J Infect Dis (2007) 0.96
A glycosylphosphatidylinositol-based treatment alleviates trypanosomiasis-associated immunopathology. J Immunol (2007) 0.96
Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology (2011) 0.96
Role of iron homeostasis in trypanosomiasis-associated anemia. Immunobiology (2008) 0.96